<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297348</url>
  </required_header>
  <id_info>
    <org_study_id>0858A2-4406</org_study_id>
    <secondary_id>B3121004</secondary_id>
    <nct_id>NCT01297348</nct_id>
    <nct_alias>NCT01316640</nct_alias>
  </id_info>
  <brief_title>Study Of Lybrel In Relation To Venous Thromboembolism</brief_title>
  <official_title>Postmarketing Study Of Lybrel In Relation To Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Collaborative Drug Surveillance Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lybrel® is an oral contraceptive that delivers low doses of levonorgestrel and ethinyl
      estradiol (90 μg/20 μg). Lybrel is taken on a continuous basis without a placebo or pill-free
      interval to inhibit menstrual cycle bleeding by delivering a steady level of the 2 hormones
      for as long as the drug is used. Lybrel was marketed in the US in July of 2007. The objective
      of this database case-control study is to estimate the risk of idiopathic VTE (deep vein
      thrombosis and pulmonary embolism) in current users of Lybrel (ethinyl estradiol
      20ug/levonorgestrel 90ug) compared to current users of other oral contraceptives containing
      20μg of ethinyl estradiol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The base population consists of all currently available data on current users (15-49 years
      old) of Lybrel and other oral contraceptives (OC) containing 20 µg ethinyl estradiol in the
      PharMetrics/IMS and MarketScan databases. From among the base population, the databases are
      then searched for any diagnosis of deep vein thrombosis (DVT), pulmonary embolism (PE), or
      cerebral venous sinus thrombosis (CVST) [referred to collectively as venous thromboembolism
      or VTE] that occurred after receipt of Lybrel or other oral contraceptives containing 20 µg
      ethinyl estradiol. The intent is to include newly diagnosed cases of VTE.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Rate of Idiopathic Venous Thromboembolism (VTE)</measure>
    <time_frame>Index date (date of VTE diagnosis for case and corresponding date for matched control)</time_frame>
    <description>Idiopathic VTE=deep vein thrombosis (DVT), pulmonary embolism (PE), or cerebral venous sinus thrombosis (CVST) occurring in absence of known risk factors. Incidence rate reported for current, past users. Current user=had claim for study OC prescription (Lybrel or other OCs containing ethinyl estradiol 20 mcg) whose filled use occurred within 30 days prior to or at index date. Past user=had claim for a study OC prescription whose filled use occurred between 90 to 31 days prior to index date. Index date=date of VTE diagnosis for case and corresponding date for matched control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Idiopathic Venous Thromboembolism (VTE) Cases and Matched Controls</measure>
    <time_frame>Index date (date of VTE diagnosis for case and corresponding date for matched control)</time_frame>
    <description>Idiopathic VTE cases=new DVT, PE or CVST occurring in absence of known risk factors. Matched Control was defined as participants with no diagnosis of VTE matched for age, calendar time, exposure status and database. Current user=had claim for study OC prescription (Lybrel or other OCs containing ethinyl estradiol 20 mcg) whose filled use occurred within 30 days prior to or at index date. Past user=had claim for a study OC prescription whose filled use occurred between 90 to 31 days prior to index date. Index date=date of VTE diagnosis for case and corresponding date for matched control.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">598682</enrollment>
  <condition>Venous Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Sinus Thrombosis, Intracranial</condition>
  <arm_group>
    <arm_group_label>Lybrel®</arm_group_label>
    <description>Current users of 90 ug levonorgestrel / 20 ug ethinyl estradiol - cases and controls (i.e., women diagnosed with new venus thromboembolism [VTE] and women not diagnosed with VTE).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other OCs containing 20μg of ethinyl estradiol</arm_group_label>
    <description>Current users of oral contraceptives containing 20μg of ethinyl estradiol - cases and controls (i.e. women diagnosed with new VTE and women not diagnosed with VTE)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90ug levonorgestrel / 20 ug ethinyl estradiol</intervention_name>
    <description>This is a non-interventional observational database study, thus no interventions are offered to patients in the study.</description>
    <arm_group_label>Lybrel®</arm_group_label>
    <other_name>Lybrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptives containing 20 ug of ethinyl estradiol</intervention_name>
    <description>This is a non-interventional observational database study, thus no interventions are offered to patients in the study.</description>
    <arm_group_label>Other OCs containing 20μg of ethinyl estradiol</arm_group_label>
    <other_name>Lessina, Aviane, Junel 1/20, Junel FE 1/20, Levlite, Lutera, Alesse, Loestrin FE 1/20, Loestrin 1/20, Microgestin 1/20, Microgestin FE 1/20</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The base population for each year of the study will comprise all 15 - 49 year old women who
        have any recorded prescriptions for either continuous use ethinyl estradiol
        20ug/levonorgestrel 90ug or a cyclic oral contraceptive that contains 20 µg ethinyl
        estradiol. The women are identified from PharMetrics and MarketScan databases.
        Additionally, women are enrolled if the index prescription is a new one; this is defined as
        a prescription dispensed following a 4-month window in which no combined hormonal
        contraception prescriptions were filled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New users of the study drugs (i.e., Lybrel and the comparison OCs)

        Exclusion Criteria:

          -  No specific exclusion criteria for the base study cohort.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=0858A2-4406&amp;StudyName=Study%20Of%20Lybrel%20In%20Relation%20To%20Venous%20Thromboembolism</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2011</study_first_posted>
  <results_first_submitted>April 2, 2013</results_first_submitted>
  <results_first_submitted_qc>April 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 27, 2013</results_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lybrel</keyword>
  <keyword>levonorgestrel</keyword>
  <keyword>ethinyl estradiol</keyword>
  <keyword>venus thromboembolism (VTE)</keyword>
  <keyword>oral contraceptives (OC)</keyword>
  <keyword>safety</keyword>
  <keyword>database study</keyword>
  <keyword>case-control study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Sinus Thrombosis, Intracranial</mesh_term>
    <mesh_term>Intracranial Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lybrel</title>
          <description>Participants who were current or past users of Lybrel, a continuous use oral contraceptive containing levonorgestrel 90 microgram (mcg) and ethinyl estradiol 20 mcg, were observed.</description>
        </group>
        <group group_id="P2">
          <title>Other OCs: Ethinyl Estradiol 20 Mcg (EE-20)</title>
          <description>Participants who were current or past users of EE-20, cyclic oral contraceptives (OCs) containing ethinyl estradiol 20 mcg and a progestin, were observed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12281"/>
                <participants group_id="P2" count="586401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12281"/>
                <participants group_id="P2" count="586401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lybrel</title>
          <description>Participants who were current or past users of Lybrel, a continuous use oral contraceptive containing levonorgestrel 90 microgram (mcg) and ethinyl estradiol 20 mcg, were observed.</description>
        </group>
        <group group_id="B2">
          <title>Other OCs: Ethinyl Estradiol 20 Mcg (EE-20)</title>
          <description>Participants who were current or past users of EE-20, cyclic oral contraceptives (OCs) containing ethinyl estradiol 20 mcg and a progestin, were observed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12281"/>
            <count group_id="B2" value="586401"/>
            <count group_id="B3" value="598682"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>15 to 19 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1549"/>
                    <measurement group_id="B2" value="151591"/>
                    <measurement group_id="B3" value="153140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 to 24 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1785"/>
                    <measurement group_id="B2" value="128757"/>
                    <measurement group_id="B3" value="130542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 to 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1925"/>
                    <measurement group_id="B2" value="99632"/>
                    <measurement group_id="B3" value="101557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to 34 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2079"/>
                    <measurement group_id="B2" value="79184"/>
                    <measurement group_id="B3" value="81263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35 to 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2074"/>
                    <measurement group_id="B2" value="56674"/>
                    <measurement group_id="B3" value="58748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1668"/>
                    <measurement group_id="B2" value="41299"/>
                    <measurement group_id="B3" value="42967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1201"/>
                    <measurement group_id="B2" value="29264"/>
                    <measurement group_id="B3" value="30465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12281"/>
                    <measurement group_id="B2" value="586401"/>
                    <measurement group_id="B3" value="598682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Participants With Duration in Health Plan Before First Study OC Prescription</title>
          <description>Duration in health plan was categorized into 4 categories: 6 to 12, 12 to 24, 24 to 60 and more than 60 months. Health plan was referred to the managed care plans which included information on paid claims for pharmaceuticals, medical diagnoses, procedures and demographic information on the participants.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6 to 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6"/>
                    <measurement group_id="B2" value="24.0"/>
                    <measurement group_id="B3" value="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 to 24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1"/>
                    <measurement group_id="B2" value="31.9"/>
                    <measurement group_id="B3" value="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 to 60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.5"/>
                    <measurement group_id="B2" value="37.0"/>
                    <measurement group_id="B3" value="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than 60 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8"/>
                    <measurement group_id="B2" value="7.1"/>
                    <measurement group_id="B3" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Obese Participants</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7"/>
                    <measurement group_id="B2" value="3.0"/>
                    <measurement group_id="B3" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Participants With Gynecological Disorders</title>
          <description>Percentage of participants were reported for following gynecological disorders: endometriosis, menstrual disorder and uterine leiomyoma.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Endometriosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.3"/>
                    <measurement group_id="B2" value="1.1"/>
                    <measurement group_id="B3" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Menstrual disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8"/>
                    <measurement group_id="B2" value="24.8"/>
                    <measurement group_id="B3" value="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterine leiomyoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.1"/>
                    <measurement group_id="B2" value="0.0"/>
                    <measurement group_id="B3" value="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Participants With Back Pain</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.0"/>
                    <measurement group_id="B2" value="8.5"/>
                    <measurement group_id="B3" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Participants With Cardiovascular Disease</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.3"/>
                    <measurement group_id="B2" value="2.8"/>
                    <measurement group_id="B3" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Participants With Hypertension</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.3"/>
                    <measurement group_id="B2" value="3.7"/>
                    <measurement group_id="B3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Participants With Hyperlipidemia</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9"/>
                    <measurement group_id="B2" value="5.5"/>
                    <measurement group_id="B3" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Participants With Diabetes</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2"/>
                    <measurement group_id="B2" value="1.7"/>
                    <measurement group_id="B3" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Participants With Asthma</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9"/>
                    <measurement group_id="B2" value="6.8"/>
                    <measurement group_id="B3" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Participants With Thyroid Disease</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.8"/>
                    <measurement group_id="B2" value="0.8"/>
                    <measurement group_id="B3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of Participants With Length of Stay in Health Plan</title>
          <description>Length of stay in health plan was categorized into: less than 1, 1 to 2, 3 to 4 and greater than or equal to 5 years. Health plan was referred to the managed care plans which included information on paid claims for pharmaceuticals, medical diagnoses, procedures and demographic information on the participants.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7"/>
                    <measurement group_id="B2" value="4.4"/>
                    <measurement group_id="B3" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 to 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6"/>
                    <measurement group_id="B2" value="16.8"/>
                    <measurement group_id="B3" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 to 4 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8"/>
                    <measurement group_id="B2" value="41.6"/>
                    <measurement group_id="B3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.0"/>
                    <measurement group_id="B2" value="37.2"/>
                    <measurement group_id="B3" value="77.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of Idiopathic Venous Thromboembolism (VTE)</title>
        <description>Idiopathic VTE=deep vein thrombosis (DVT), pulmonary embolism (PE), or cerebral venous sinus thrombosis (CVST) occurring in absence of known risk factors. Incidence rate reported for current, past users. Current user=had claim for study OC prescription (Lybrel or other OCs containing ethinyl estradiol 20 mcg) whose filled use occurred within 30 days prior to or at index date. Past user=had claim for a study OC prescription whose filled use occurred between 90 to 31 days prior to index date. Index date=date of VTE diagnosis for case and corresponding date for matched control.</description>
        <time_frame>Index date (date of VTE diagnosis for case and corresponding date for matched control)</time_frame>
        <population>Analysis population included all enrolled participants who met the eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Lybrel</title>
            <description>Participants who were current or past users of Lybrel, a continuous use oral contraceptive containing levonorgestrel 90 microgram (mcg) and ethinyl estradiol 20 mcg, were observed.</description>
          </group>
          <group group_id="O2">
            <title>Other OCs: Ethinyl Estradiol 20 Mcg (EE-20)</title>
            <description>Participants who were current or past users of EE-20, cyclic oral contraceptives (OCs) containing ethinyl estradiol 20 mcg and a progestin, were observed.</description>
          </group>
          <group group_id="O3">
            <title>Other OCs: Levonorgestrel, Ethinyl Estradiol 20 Mcg (Levo-20)</title>
            <description>A subset of EE-20 group including participants who were current or past users of Levo-20, cyclic oral contraceptives (OCs) containing ethinyl estradiol 20 mcg and differing concentrations of levonorgestrel (progestin), were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Idiopathic Venous Thromboembolism (VTE)</title>
          <description>Idiopathic VTE=deep vein thrombosis (DVT), pulmonary embolism (PE), or cerebral venous sinus thrombosis (CVST) occurring in absence of known risk factors. Incidence rate reported for current, past users. Current user=had claim for study OC prescription (Lybrel or other OCs containing ethinyl estradiol 20 mcg) whose filled use occurred within 30 days prior to or at index date. Past user=had claim for a study OC prescription whose filled use occurred between 90 to 31 days prior to index date. Index date=date of VTE diagnosis for case and corresponding date for matched control.</description>
          <population>Analysis population included all enrolled participants who met the eligibility criteria.</population>
          <units>incidence rate per 100000 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12281"/>
                <count group_id="O2" value="586401"/>
                <count group_id="O3" value="142860"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Current users</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.2"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past users</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1"/>
                    <measurement group_id="O2" value="18.0"/>
                    <measurement group_id="O3" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Incidence rate ratio (Lybrel/EE-20) along with corresponding 95 percent (%) confidence interval (CI) was reported for current users.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence rate ratio</param_type>
            <param_value>2.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Incidence rate ratio (Lybrel/EE-20) along with corresponding 95% CI was reported for past users.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence rate ratio</param_type>
            <param_value>2.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>22.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Incidence rate ratio (Lybrel/Levo-20) along with corresponding 95% CI was reported for current users.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence rate ratio</param_type>
            <param_value>3.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.02</ci_lower_limit>
            <ci_upper_limit>6.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Incidence rate ratio (Lybrel/Levo-20) along with corresponding 95% CI was reported for past users.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Incidence rate ratio</param_type>
            <param_value>3.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>27.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Idiopathic Venous Thromboembolism (VTE) Cases and Matched Controls</title>
        <description>Idiopathic VTE cases=new DVT, PE or CVST occurring in absence of known risk factors. Matched Control was defined as participants with no diagnosis of VTE matched for age, calendar time, exposure status and database. Current user=had claim for study OC prescription (Lybrel or other OCs containing ethinyl estradiol 20 mcg) whose filled use occurred within 30 days prior to or at index date. Past user=had claim for a study OC prescription whose filled use occurred between 90 to 31 days prior to index date. Index date=date of VTE diagnosis for case and corresponding date for matched control.</description>
        <time_frame>Index date (date of VTE diagnosis for case and corresponding date for matched control)</time_frame>
        <population>Analysis population included all enrolled participants who met the eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Lybrel</title>
            <description>Participants who were current or past users of Lybrel, a continuous use oral contraceptive containing levonorgestrel 90 microgram (mcg) and ethinyl estradiol 20 mcg, were observed.</description>
          </group>
          <group group_id="O2">
            <title>Other OCs: Ethinyl Estradiol 20 Mcg (EE-20)</title>
            <description>Participants who were current or past users of EE-20, cyclic oral contraceptives (OCs) containing ethinyl estradiol 20 mcg and a progestin, were observed.</description>
          </group>
          <group group_id="O3">
            <title>Other OCs: Levonorgestrel, Ethinyl Estradiol 20 Mcg (Levo-20)</title>
            <description>A subset of EE-20 group including participants who were current or past users of Levo-20, cyclic oral contraceptives (OCs) containing ethinyl estradiol 20 mcg and differing concentrations of levonorgestrel (progestin), were observed.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Idiopathic Venous Thromboembolism (VTE) Cases and Matched Controls</title>
          <description>Idiopathic VTE cases=new DVT, PE or CVST occurring in absence of known risk factors. Matched Control was defined as participants with no diagnosis of VTE matched for age, calendar time, exposure status and database. Current user=had claim for study OC prescription (Lybrel or other OCs containing ethinyl estradiol 20 mcg) whose filled use occurred within 30 days prior to or at index date. Past user=had claim for a study OC prescription whose filled use occurred between 90 to 31 days prior to index date. Index date=date of VTE diagnosis for case and corresponding date for matched control.</description>
          <population>Analysis population included all enrolled participants who met the eligibility criteria.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12281"/>
                <count group_id="O2" value="586401"/>
                <count group_id="O3" value="142860"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Current user: Case</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="276"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current user: Matched Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="1144"/>
                    <measurement group_id="O3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past user: Case</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past user: Matched Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Current user, case and matched control: Odds ratio (Lybrel/EE-20) and 95% CI were estimated using conditional logistic regression, conditional on matching factors (age, calendar time, exposure status and database).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>2.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Current user, case and matched control: Odds ratio (Lybrel/Levo-20) and 95% CI were estimated using conditional logistic regression, conditional on matching factors (age, calendar time, exposure status and database).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>6.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The minimum criteria for reporting an adverse event (AE) (that is, identifiable participant, identifiable reporter, a suspect product, and event) were not available and adverse events were not reportable as individual AE reports in this observational non-interventional study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lybrel</title>
          <description>Participants who were current or past users of Lybrel, a continuous use oral contraceptive containing levonorgestrel 90 microgram (mcg) and ethinyl estradiol 20 mcg, were observed.</description>
        </group>
        <group group_id="E2">
          <title>Other OCs: Ethinyl Estradiol 20 Mcg (EE-20)</title>
          <description>Participants who were current or past users of EE-20, cyclic oral contraceptives (OCs) containing ethinyl estradiol 20 mcg and a progestin, were observed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data for DVT, PE and CVST were not reported separately as the 3 were components of the primary endpoint VTE and not separate endpoints.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquires@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

